{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Water&page=24",
    "query": {
      "intervention": "Water",
      "page": 24
    },
    "page_size": 10
  },
  "pagination": {
    "page": 24,
    "page_size": 10,
    "total_count": 3255,
    "total_pages": 326,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Water&page=25&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Water&page=23&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-19T08:21:15.279Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03279731",
      "title": "Binge Eating Liraglutide Intervention",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Binge-Eating Disorder"
      ],
      "interventions": [
        {
          "name": "Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kelly Allison",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "21 Years to 70 Years"
      },
      "enrollment_count": 36,
      "start_date": "2017-09-29",
      "completion_date": "2019-10-01",
      "has_results": true,
      "last_update_posted_date": "2020-11-24",
      "last_synced_at": "2026-10-19T08:21:15.279Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03279731"
    },
    {
      "nct_id": "NCT01509339",
      "title": "Pharmacokinetics of Vancomycin for Inhalation in Cystic Fibrosis",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cystic Fibrosis",
        "Methicillin-resistant Staphylococcus Aureus"
      ],
      "interventions": [
        {
          "name": "Vancomycin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Case Western Reserve University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2012-01",
      "completion_date": "2021-12-23",
      "has_results": false,
      "last_update_posted_date": "2022-01-12",
      "last_synced_at": "2026-10-19T08:21:15.279Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01509339"
    },
    {
      "nct_id": "NCT03938441",
      "title": "Biweekly Interval Intermittent Fasting for Type 2 Diabetes, a Safety Study",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Diabetes Type 2",
        "Pre-diabetes"
      ],
      "interventions": [
        {
          "name": "Intermittent Fasting",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "gino gaddini",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "69 Years",
        "sex": "ALL",
        "summary": "18 Years to 69 Years"
      },
      "enrollment_count": 24,
      "start_date": "2019-07-31",
      "completion_date": "2021-05-28",
      "has_results": false,
      "last_update_posted_date": "2021-06-04",
      "last_synced_at": "2026-10-19T08:21:15.279Z",
      "location_count": 1,
      "location_summary": "Nellis Air Force Base, Nevada",
      "locations": [
        {
          "city": "Nellis Air Force Base",
          "state": "Nevada"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03938441"
    },
    {
      "nct_id": "NCT06390956",
      "title": "Pirtobrutinib in Combination With Rituximab in Adults With Untreated Marginal Zone Lymphoma (PIONEER-MZL)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Marginal Zone Lymphoma"
      ],
      "interventions": [
        {
          "name": "Pirtobrutinib",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Utah",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 23,
      "start_date": "2025-02-20",
      "completion_date": "2032-12",
      "has_results": false,
      "last_update_posted_date": "2025-12-04",
      "last_synced_at": "2026-10-19T08:21:15.279Z",
      "location_count": 2,
      "location_summary": "St Louis, Missouri • Salt Lake City, Utah",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06390956"
    },
    {
      "nct_id": "NCT04534322",
      "title": "Expanded Access Program for Melphalan Flufenamide (Melflufen) in Triple Class Refractory Multiple Myeloma",
      "overall_status": "APPROVED_FOR_MARKETING",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "Relapsed and/or Refractory Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Melphalan Flufenamide",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Oncopeptides AB",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2021-03-18",
      "last_synced_at": "2026-10-19T08:21:15.279Z",
      "location_count": 11,
      "location_summary": "Springdale, Arkansas • Coeur d'Alene, Idaho • Chicago, Illinois + 8 more",
      "locations": [
        {
          "city": "Springdale",
          "state": "Arkansas"
        },
        {
          "city": "Coeur d'Alene",
          "state": "Idaho"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Canton",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04534322"
    },
    {
      "nct_id": "NCT04193631",
      "title": "Low Dose of Cannabidiol (CBD) to Treat Mild to Moderate Musculoskeletal Pain",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Musculoskeletal Pain"
      ],
      "interventions": [
        {
          "name": "Cannabidiol (CBD)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pure Green",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2019-12-07",
      "completion_date": "2019-12-09",
      "has_results": false,
      "last_update_posted_date": "2020-03-24",
      "last_synced_at": "2026-10-19T08:21:15.279Z",
      "location_count": 1,
      "location_summary": "Chadds Ford, Pennsylvania",
      "locations": [
        {
          "city": "Chadds Ford",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04193631"
    },
    {
      "nct_id": "NCT00935753",
      "title": "Trial of Kuvan in Lesch-Nyhan Disease",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Behavioral Manifestations of Lesch-Nyhan Disease"
      ],
      "interventions": [
        {
          "name": "sapropterin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Diego",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "4 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2009-04",
      "completion_date": "2010-02",
      "has_results": false,
      "last_update_posted_date": "2019-08-02",
      "last_synced_at": "2026-10-19T08:21:15.279Z",
      "location_count": 1,
      "location_summary": "San Diego, California",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00935753"
    },
    {
      "nct_id": "NCT01250977",
      "title": "Effect of Donepezil on Smoking",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Smoking"
      ],
      "interventions": [
        {
          "name": "Donepezil",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Abramson Cancer Center at Penn Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 30,
      "start_date": "2011-01-11",
      "completion_date": "2011-12-06",
      "has_results": true,
      "last_update_posted_date": "2019-07-11",
      "last_synced_at": "2026-10-19T08:21:15.279Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01250977"
    },
    {
      "nct_id": "NCT00393029",
      "title": "Phase II Study of Metastatic Cancer That Overexpresses P53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-P53 TCR-Gene Engineered Lymphocytes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Anti-p53 TCR-Gene"
      ],
      "interventions": [
        {
          "name": "anti-protein 53 or tumor protein 53 (p53) T-cell receptor transduced peripheral blood lymphocytes",
          "type": "BIOLOGICAL"
        },
        {
          "name": "aldesleukin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "fludarabine phosphate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2006-10",
      "completion_date": "2008-11",
      "has_results": true,
      "last_update_posted_date": "2011-08-15",
      "last_synced_at": "2026-10-19T08:21:15.279Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00393029"
    },
    {
      "nct_id": "NCT05413395",
      "title": "Assessment of the Effects on the Skin Microbiome of Amending an Over-the-counter Eczema Product With Activated Oil (AO)",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Eczema"
      ],
      "interventions": [
        {
          "name": "topical colloidal oatmeal formulation with a modified plant oil",
          "type": "OTHER"
        },
        {
          "name": "topical colloidal oatmeal formulation",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "GlycosBio, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2022-06-17",
      "completion_date": "2024-03-01",
      "has_results": false,
      "last_update_posted_date": "2022-07-05",
      "last_synced_at": "2026-10-19T08:21:15.279Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05413395"
    }
  ]
}